Gline Matthew
SEC CIK 1750094 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| ROIV | Roivant Sciences Ltd. | CEO, Dir | 16.66M | $50.0K | $71.78M | 67 | 2022-03-07 | 2026-06-30 |
Most active insiders at ROIV, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | MANCHESTER KEITH S | Dir | — | $154.47M |
| 2 | Gold Daniel Allen | Dir | — | $147.38M |
| 3 | QVT Financial LP | Dir by Deputization | — | $147.38M |
| 4 | Sukhatme Mayukh | Pres, CIO, Dir | — | $109.13M |
| 5 | Ramaswamy Vivek | 10% | — | $105.88M |
| 6 | Venker Eric | Pres, Immunovant CEO | — | $89.77M |
| 7 | Torti Frank | Pres, Vant COB | — | $82.04M |
| 8 | Gline Matthew | CEO, Dir | — | $46.17M |
| 9 | Pulik Richard | CFO | — | $9.12M |
| 10 | Fitzgerald Meghan | Dir | — | $3.27M |
Transactions 67
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-02 19:06 | 2026-06-30 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | F - Tax | $35.39 | -76.2K | 16.66M | -0.5% | -$2.70M | |
| 2026-04-20 18:27 | 2026-04-16 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | S - Sale | $29.16 | -289.8K | 16.74M | -2% | -$8.45M | |
| D | 2026-04-01 19:20 | 2026-03-30 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | M - OptEx | — | +97.3K | 17.38M | +0.6% | — |
| DM | 2026-04-01 19:20 | 2026-03-30+ | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | F - Tax | $27.51 | -358.5K | 17.03M | -2% | -$9.86M |
| DM | 2025-12-17 | 2025-12-15 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | S - Sale+OE | $21.68 | -1.74M | 18.08M | -9% | -$37.72M |
| DM | 2025-12-17 | 2025-12-15 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | J - Other | $21.68 | -2.13M | 17.29M | -11% | -$46.19M |
| DM | 2025-12-17 | 2025-12-15 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | M - OptEx | $12.16 | +3.87M | 18.65M | +26% | +$47.06M |
| 2025-09-18 | 2025-09-18 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | P - Purchase | $15.07 | +3,315 | 17.29M | +0.0% | +$50.0K | |
| 2025-05-22 | 2025-05-20 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | F - Tax | $11.04 | -10.9K | 17.28M | -0.1% | -$120.8K | |
| 2025-04-22 | 2025-04-20 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | F - Tax | $10.15 | -10.9K | 17.29M | -0.1% | -$111.1K | |
| 2025-03-24 | 2025-03-20 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | F - Tax | $10.97 | -10.9K | 17.31M | -0.1% | -$120.1K | |
| 2025-02-24 | 2025-02-20 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | F - Tax | $10.72 | -10.9K | 17.32M | -0.1% | -$117.3K | |
| 2025-01-22 | 2025-01-20 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | F - Tax | $11.15 | -11.6K | 17.33M | -0.1% | -$129.6K | |
| 2024-12-26 | 2024-12-20 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | F - Tax | $11.57 | -10.9K | 17.34M | -0.1% | -$126.6K | |
| 2024-11-22 | 2024-11-20 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | F - Tax | $11.49 | -10.9K | 17.35M | -0.1% | -$125.8K | |
| 2024-10-22 | 2024-10-20 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | F - Tax | $11.92 | -10.9K | 17.36M | -0.1% | -$130.5K | |
| DT | 2024-09-24 | 2024-09-23 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | J - Other | $11.97 | -498.5K | 17.37M | -3% | -$5.97M |
| DT | 2024-09-24 | 2024-09-23 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | S - Sale+OE | $11.79 | -1.98M | 17.87M | -10% | -$23.38M |
| DT | 2024-09-24 | 2024-09-23 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | M - OptEx | $3.85 | +1.55M | 19.85M | +8% | +$5.97M |
| DT | 2024-09-24 | 2024-09-20 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | F - Tax | $11.97 | -10.9K | 18.30M | -0.1% | -$131.0K |
| T | 2024-08-22 | 2024-08-20 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | F - Tax | $11.48 | -10.9K | 18.31M | -0.1% | -$125.7K |
| M | 2024-07-30 | 2024-07-26 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | A - Grant | $0.00 | +17.20M | 3.88M | New | $0 |
| T | 2024-07-25 | 2024-07-20 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | F - Tax | $11.00 | -10.9K | 1.12M | -1.0% | -$120.4K |
| T | 2024-06-24 | 2024-06-20 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | F - Tax | $10.80 | -10.9K | 1.13M | -1.0% | -$118.2K |
| T | 2024-05-22 | 2024-05-20 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | F - Tax | $11.37 | -10.9K | 1.14M | -0.9% | -$124.4K |
| T | 2024-04-23 | 2024-04-20 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | F - Tax | $10.46 | -10.9K | 1.15M | -0.9% | -$114.5K |
| DT | 2024-04-02 | 2024-03-30 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | M - OptEx | — | +390.6K | 1.38M | +39% | — |
| DT | 2024-04-02 | 2024-03-30 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | F - Tax | $10.54 | -216.0K | 1.16M | -16% | -$2.28M |
| T | 2024-03-22 | 2024-03-20 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | F - Tax | $10.01 | -10.9K | 990.1K | -1% | -$109.6K |
| T | 2024-02-22 | 2024-02-20 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | F - Tax | $11.54 | -10.9K | 1.00M | -1% | -$126.3K |
| T | 2024-01-23 | 2024-01-20 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | F - Tax | $10.35 | -10.9K | 1.01M | -1% | -$113.3K |
| DT | 2023-12-29 | 2023-12-27 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | M - OptEx | — | +38.5K | 1.04M | +4% | — |
| DT | 2023-12-29 | 2023-12-27 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | F - Tax | $11.58 | -22.0K | 1.02M | -2% | -$255.3K |
| T | 2023-12-22 | 2023-12-20 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | F - Tax | $9.96 | -10.9K | 1.01M | -1% | -$109.0K |
| T | 2023-11-27 | 2023-11-22 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | J - Other | $8.68 | -11.3K | 1.02M | -1% | -$98.2K |
| T | 2023-10-26 | 2023-10-24 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | J - Other | $8.99 | -12.5K | 1.03M | -1% | -$112.3K |
| D | 2023-09-29 | 2023-09-28 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | J - Other | $12.67 | -10.2K | 1.04M | -1.0% | -$129.8K |
| D | 2023-09-29 | 2023-09-27 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | M - OptEx | — | +17.8K | 1.05M | +2% | — |
| 2023-09-26 | 2023-09-22 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | J - Other | $10.19 | -11.2K | 1.03M | -1% | -$114.4K | |
| D | 2023-08-29 | 2023-08-28 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | J - Other | $11.25 | -6,784 | 1.04M | -0.6% | -$76.3K |
| D | 2023-08-29 | 2023-08-27 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | M - OptEx | — | +12.1K | 1.05M | +1% | — |
| 2023-08-24 | 2023-08-22 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | J - Other | $10.83 | -11.0K | 1.04M | -1% | -$119.3K | |
| 2023-08-03 | 2023-08-02 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | J - Other | $11.79 | -11.7K | 1.05M | -1% | -$138.5K | |
| D | 2023-07-31 | 2023-07-27 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | M - OptEx | — | +23.1K | 1.06M | +2% | — |
| 2023-07-26 | 2023-07-24 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | J - Other | $10.99 | -11.1K | 1.04M | -1% | -$122.5K | |
| 2023-06-26 | 2023-06-22 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | J - Other | $10.01 | -10.9K | 1.05M | -1% | -$108.7K | |
| D | 2023-05-31 | 2023-05-31 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | J - Other | $9.09 | -30.3K | 1.06M | -3% | -$275.1K |
| D | 2023-05-31 | 2023-05-27 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | M - OptEx | — | +53.3K | 1.09M | +5% | — |
| 2023-05-25 | 2023-05-23 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | J - Other | $9.58 | -19.0K | 1.04M | -2% | -$181.8K | |
| 2023-04-24 | 2023-04-20 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | F - Tax | $8.80 | -19.4K | 1.06M | -2% | -$170.5K | |
| 2023-03-27 | 2023-03-23 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | J - Other | $7.30 | -18.6K | 1.08M | -2% | -$135.5K | |
| 2023-02-24 | 2023-02-22 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | J - Other | $8.43 | -14.5K | 1.10M | -1% | -$122.0K | |
| 2023-01-26 | 2023-01-24 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | J - Other | $8.56 | -15.6K | 1.11M | -1% | -$133.5K | |
| 2022-12-28 | 2022-12-23 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | J - Other | $7.10 | -19.4K | 1.13M | -2% | -$137.8K | |
| 2022-11-22 | 2022-11-20 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | J - Other | $5.00 | -19.4K | 1.14M | -2% | -$96.9K | |
| 2022-10-27 | 2022-10-25 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | S - Sale | $4.40 | -19.3K | 1.16M | -2% | -$84.8K | |
| 2022-09-27 | 2022-09-23 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | S - Sale | $3.07 | -21.1K | 1.18M | -2% | -$64.6K | |
| 2022-08-26 | 2022-08-24 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | S - Sale | $3.71 | -20.0K | 1.20M | -2% | -$74.2K | |
| 2022-07-27 | 2022-07-25 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | S - Sale | $4.33 | -20.5K | 1.22M | -2% | -$88.6K | |
| 2022-06-27 | 2022-06-23 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | S - Sale | $4.34 | -19.9K | 1.24M | -2% | -$86.2K | |
| 2022-05-24 | 2022-05-20 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | S - Sale | $3.70 | -139.8K | 1.26M | -10% | -$517.2K | |
| 2022-04-27 | 2022-04-25 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | S - Sale | $3.84 | -8,509 | 1.40M | -0.6% | -$32.7K | |
| 2022-04-01 | 2022-03-30 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | F - Tax | $4.74 | -25.3K | 1.41M | -2% | -$119.7K | |
| 2022-04-01 | 2022-03-30 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | S - Sale | $4.84 | -33.7K | 1.44M | -2% | -$163.0K | |
| 2022-03-29 | 2022-03-25 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | S - Sale | $5.06 | -35.4K | 1.47M | -2% | -$179.1K | |
| 2022-03-22 | 2022-03-18 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | S - Sale | $5.13 | -82.0K | 1.51M | -5% | -$420.7K | |
| 2022-03-09 | 2022-03-07 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO, Dir | S - Sale | $5.52 | -92.3K | 1.59M | -5% | -$509.6K |
Purchase Sale Sale after option exercise All abbreviations